Doxapram

Respiratory center depression is a common critical complication in scenarios such as post-anesthesia surgery and drug poisoning, which can directly threaten the life safety of patients in severe cases. Doxapram, as an API for respiratory stimulants, is a non-specific respiratory stimulant. It directly stimulates the respiratory center of the medulla oblongata and acts on the carotid body chemoreceptors to enhance the sensitivity of the respiratory center to carbon dioxide, thereby accelerating respiratory rate and increasing tidal volume. It is clinically mainly used for arousal after general anesthesia, respiratory failure caused by poisoning of central depressant drugs, and respiratory insufficiency associated with chronic obstructive pulmonary disease. The applicable population covers perioperative patients, patients receiving treatment for drug poisoning and people with acute attacks of chronic respiratory diseases.

At present, the global doxapram market size is stable at around USD 230 million, with a compound annual growth rate of 3.1%. The growth momentum mainly comes from the release of demand for post-anesthesia arousal in primary medical institutions and the popularization of emergency treatment scenarios. In the domestic market, generic drugs account for more than 90%. After the implementation of centralized procurement, the terminal price of the preparation of this drug has dropped by 67%, further driving the increase in demand for APIs. The current annual domestic demand for doxapram API is about 12 tons, and the top 3 manufacturers occupy 85% of the market share.

The original research enterprise of doxapram is Hospira Inc, and the original research trade name is Dopram. The core compound patent in the United States expired in 1986. The main dosage forms of the original research are injections, with specifications including 20ml:400mg and 5ml:100mg. They have been included in the FDA Reference Listed Drug Catalog, but have not been included in the domestic Reference Listed Drug Catalog. As of now, 3 domestic enterprises have obtained A-status registration numbers for doxapram APIs, and another 2 enterprises have registration numbers in I status. Doxapram injection preparations have been approved for marketing in China. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO provides a full set of doxapram impurity reference standards, which can cover the needs of all research scenarios such as process impurities and degradation impurities. Most products are in stock. Orders placed before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can directly support relevant work such as quality research and registration declaration of APIs.